Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncogene. 2007 Jul 5;26(31):4596-9. Epub 2007 Jan 22.

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Author information

  • 1Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115-6110, USA.

Erratum in

  • Oncogene. 2007 Aug 16;26(38):5692.

Abstract

The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio=2.7, P<0.01, 95% confidence interval=1.3-5.8). Quantitative reverse-transcription-polymerase chain reaction demonstrated high ets-related [corrected] gene (ERG) expression to be associated with TMPRSS2:ERG fusion (P<0.005). These data suggest that TMPRSS2:ERG fusion prostate cancers may have a more aggressive phenotype, possibly mediated through increased ERG expression.

PMID:
17237811
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk